93 results
S-8 POS
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees (post-effective amendment)
5:12pm
duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and executive officers even though an action … . At present, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers
S-8
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and executive officers even though an action … provisions. At present, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including
8-K
EX-99.1
7f038ve8qjxzex9j
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
8-K
EX-99.1
k0ug72r1vps78d04
4 Mar 24
Other Events
4:52pm
424B5
reqyt
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
EX-99.1
4c9oo52
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
o8tt99 hdbe1inwmh
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
1ql5l l7h
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
rm5rki1c
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
z9fh3 1dnpbzon
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
8qluugadjs 7ikz8jcy
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
jtix8bhygdwas x3dk
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm